I largely agree with your views here. As an example, my sister in law (this is ten years ago) didn't accept a mammogram's results, knowing that she was high density but "feeling something", re-tested and was confirmed early stage BRCA+ trip neg.........her intuition saved her live, I spoke with her yesterday after a routine follow up scan (clear).
So the density issue, while seemingly underrated by the market is HUGELY overlooked IMO. Similarly, but yet to be proven, in the cardio space.
That being said, $ICAD is an underdog despite advanced tech, and that "advanced tech" moat is subject to erosion via AI (and time). 12 -24 months is my window for increased market share and/or a buy out.
I largely agree with your views here. As an example, my sister in law (this is ten years ago) didn't accept a mammogram's results, knowing that she was high density but "feeling something", re-tested and was confirmed early stage BRCA+ trip neg.........her intuition saved her live, I spoke with her yesterday after a routine follow up scan (clear).
So the density issue, while seemingly underrated by the market is HUGELY overlooked IMO. Similarly, but yet to be proven, in the cardio space.
That being said, $ICAD is an underdog despite advanced tech, and that "advanced tech" moat is subject to erosion via AI (and time). 12 -24 months is my window for increased market share and/or a buy out.
Thanks for the write up, well done! Long ICAD
Yes you're right, market will be looking for either continual real tech development OR real market capture. Thanks for the kind words!
Hi Mike - Im a radiologist and own about 2% of ICAD. happy to chat If you would like. thanks for bringing attention to this name.
Send me a dm!
substack message sent!
any insights that ensued from this? 😃
Thanks for this. How do you see / think regarding the management incentives, skin in the game, KPIs, etc?
KPIs should be pretty clear from the post; think I also talk about lack of insider buying being offputting
a lot of insider selling this year.
Think the article is great but misses the point on how rise in breast cancer is probably driven largely in part by the obesity epidemic